10-K/A: Unity Biotechnology Files Amendment to 10-K, Updates Executive and Director Information

Unity Biotechnology files an amendment to its 2024 Annual Report on Form 10-K to include updated information on directors, executive officers, compensation, and related matters.

Summary

• Unity Biotechnology filed an amendment to its original Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information previously omitted from Part III, Items 10 through 14, related to directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
• The company opted to file this amendment due to the timing of anticipated data from the ASPIRE study and related strategic considerations.
• The amendment includes new certifications from the principal executive officer and principal financial officer.
• The filing does not change or update any other disclosures from the original Form 10-K or reflect events occurring after the original filing date.
• As of April 10, 2025, the company's directors include Anirvan Ghosh, Keith R. Leonard Jr., Nathaniel E. David, Yehia Hashad, Gilmore O'Neill, Margo R. Roberts, Michael P. Samar, and Camille D. Samuels.
• Key executive officers include Anirvan Ghosh (CEO), Lynne Sullivan (CFO and Head of Corporate Development), Federico Grossi (CMO), and Alexander Nguyen (Chief Legal Officer and Head of Operations).
• The aggregate market value of voting and non-voting common equity held by non-affiliates of the Registrant on June 30, 2024 was $22,509,406.
• As of March 6, 2025, there were 16,867,647 shares of the Registrant's Common Stock outstanding.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing providing factual information about the company's governance and compensation practices. The sentiment is neutral to slightly positive as it reflects ongoing operations and adherence to regulatory requirements.

Positives

• The company has a diverse and experienced board of directors with expertise in various areas of the biotechnology industry.
• The executive compensation program is designed to align the interests of executives with those of shareholders through a mix of cash and equity incentives.
• The company has established corporate governance policies and procedures, including a code of business conduct and ethics and an insider trading policy.
• The Audit Committee is comprised of independent directors with financial expertise.

Future Outlook

The document does not contain specific forward-looking statements beyond the implications of the described organizational and compensation structures.

Industry Context

The document provides insight into the corporate governance and executive compensation practices of a biotechnology company, which are important factors for investors to consider when evaluating the company's performance and potential.

Comparison to Industry Standards

• The director and executive compensation structures appear consistent with those of other small to mid-sized biotechnology companies.
• The board composition includes a mix of experienced industry executives, venture capitalists, and scientific experts, which is typical for companies in this sector.
• The use of equity awards as a significant component of executive compensation is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Management Changes

Related Party Transactions

• In December 2021, Unity Biotechnology entered into a licensing agreement with Jocasta Neuroscience, Inc. (Jocasta) pursuant to which they exclusively licensed all of their rights to UBX2089, their -Klotho asset.
• A member of Unity Biotechnology's board of directors, Nathaniel David, is an affiliate of Jocasta Neuroscience, Inc., where he is serving on Jocasta's board of directors.
• The agreement provided for an upfront fee of $5.0 million.

Stakeholder Impact

• The information in this amendment is relevant to shareholders as it provides transparency regarding the company's leadership, governance, and compensation practices.
• Employees are impacted by the executive compensation program and the company's overall governance structure.
• The licensing agreement with Jocasta Neuroscience, Inc. may impact the company's future revenue and product development opportunities.

Key Dates

Keywords

executive compensation, directors, corporate governance, amendment, 10-K, Unity Biotechnology, financial reporting